GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » COGS-to-Revenue

Cangene (FRA:YGE) COGS-to-Revenue : 0.63 (As of Oct. 2013)


View and export this data going back to . Start your Free Trial

What is Cangene COGS-to-Revenue?

Cangene's Cost of Goods Sold for the three months ended in Oct. 2013 was €11.43 Mil. Its Revenue for the three months ended in Oct. 2013 was €18.04 Mil.

Cangene's COGS to Revenue for the three months ended in Oct. 2013 was 0.63.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cangene's Gross Margin % for the three months ended in Oct. 2013 was 36.67%.


Cangene COGS-to-Revenue Historical Data

The historical data trend for Cangene's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene COGS-to-Revenue Chart

Cangene Annual Data
Trend Jul04 Jul05 Jul06 Jul07 Jul08 Jul09 Jul10 Jul11 Jul12 Jul13
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.50 0.63 0.64 0.77 0.59

Cangene Quarterly Data
Jan09 Apr09 Jul09 Oct09 Jan10 Apr10 Jul10 Oct10 Jan11 Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.69 0.45 0.67 0.63

Cangene COGS-to-Revenue Calculation

Cangene's COGS to Revenue for the fiscal year that ended in Jul. 2013 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=57.322 / 97.269
=0.59

Cangene's COGS to Revenue for the quarter that ended in Oct. 2013 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=11.427 / 18.043
=0.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cangene  (FRA:YGE) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cangene's Gross Margin % for the three months ended in Oct. 2013 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 11.427 / 18.043
=36.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Cangene COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cangene's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cangene (FRA:YGE) Business Description

Traded in Other Exchanges
N/A
Address
Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines